Published in Can J Gastroenterol on January 01, 2010
Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol (2010) 1.08
Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol (2012) 1.00
Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol (2015) 0.90
Liver Transplantation for Cholestatic Liver Diseases in Adults. Clin Liver Dis (2015) 0.88
Clinical management of inflammatory bowel disease in the organ recipient. World J Gastroenterol (2014) 0.86
Liver Transplantation for Patients with Cholestatic Liver Diseases. Viszeralmedizin (2015) 0.83
Autoimmune Liver Disease Post-Liver Transplantation: A Summary and Proposed Areas for Future Research. Transplantation (2016) 0.81
Frequency and risk factors of primary sclerosing cholangitis among patients with inflammatory bowel disease in North-East of Iran. Gastroenterol Hepatol Bed Bench (2015) 0.76
Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort. PLoS One (2015) 0.76
A Review of Inflammatory Bowel Disease in the Setting of Liver Transplantation. Gastroenterol Hepatol (N Y) (2014) 0.75
Recurrence of autoimmune liver diseases after liver transplantation. World J Hepatol (2015) 0.75
Outcomes of Liver Transplant Recipients With Autoimmune Liver Disease Using Long-Term Dual Immunosuppression Regimen Without Corticosteroid. Transplant Direct (2017) 0.75
Management of ulcerative colitis pre- and post-liver transplant for primary sclerosing cholangitis: two case reports and review of literature. Int J Colorectal Dis (2014) 0.75
Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation: Guidelines on colon cancer screening. Can J Gastroenterol (2004) 5.09
Banff schema for grading liver allograft rejection: an international consensus document. Hepatology (1997) 3.22
Primary sclerosing cholangitis in ulcerative colitis--a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology (1992) 2.61
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut (1996) 2.40
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (1989) 2.39
Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut (1998) 1.63
Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl (2005) 1.52
Indications for liver transplantation in the cyclosporine era. Surg Clin North Am (1986) 1.46
Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology (1999) 1.26
Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology (2002) 1.21
Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl (2008) 1.19
Primary sclerosing cholangitis: updates in diagnosis and therapy. World J Gastroenterol (2005) 1.16
Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet (2002) 1.16
Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg (1997) 1.16
Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation (1998) 1.15
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2008) 1.14
Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology (1999) 1.14
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2008) 1.12
Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology (1998) 1.09
Cancer is a complication of severe immunosuppression. Surg Gynecol Obstet (1986) 1.06
Biliary disease after liver transplantation: the experience of the King Faisal Specialist Hospital and Research Center, Riyadh. J Gastroenterol Hepatol (2005) 1.00
Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Dig Dis Sci (1991) 0.97
The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann Surg (1992) 0.96
Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation (1998) 0.96
Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum (1993) 0.94
Primary sclerosing cholangitis. Inflamm Bowel Dis (2005) 0.94
Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum Pathol (2003) 0.94
Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis (2006) 0.92
Combination of extended donor criteria and changes in the Model for End-Stage Liver Disease score predict patient survival and primary dysfunction in liver transplantation: a retrospective analysis. Transplantation (2007) 0.89
Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease. AJR Am J Roentgenol (1996) 0.89
Liver transplantation for primary sclerosing cholangitis. Liver (2000) 0.88
Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol (1996) 0.88
Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2003) 0.88
Extended donor criteria have no negative impact on early outcome after liver transplantation: a single-center multivariate analysis. Transplant Proc (2007) 0.88
Inflammatory bowel disease in primary sclerosing cholangitis: an analysis of patients undergoing liver transplantation. Br J Surg (1995) 0.87
Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther (2003) 0.87
The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol (2005) 0.86
Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis. Eur J Gastroenterol Hepatol (2003) 0.83
Use of marginal donors for liver transplantation: a single-center experience within the Eurotransplant patient-driven allocation system. Transplant Proc (2007) 0.82
Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis. Scand J Gastroenterol (1999) 0.81
Recurrence of primary sclerosing cholangitis: what do we learn from several transplant centers? Liver Transpl (2008) 0.80
Current treatments of primary sclerosing cholangitis. Curr Med Chem (2007) 0.77
Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl (2012) 2.26
Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl (2014) 2.25
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl (2004) 1.80
Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl (2009) 1.55
Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. J Hepatol (2010) 1.53
Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol (2004) 1.43
Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes. Diabetes Care (2003) 1.29
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol (2012) 1.27
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation (2007) 1.11
Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release (2005) 1.10
The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int (2008) 0.98
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98
A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol (2009) 0.96
Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl (2002) 0.96
Managing the post-liver transplantation anastomotic biliary stricture: multiple plastic versus metal stents: a systematic review. Gastrointest Endosc (2013) 0.95
Incidence of heart failure and mortality after acute coronary syndromes. Am Heart J (2013) 0.95
Validation of the five-variable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list. Liver Int (2013) 0.92
Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians. Can J Gastroenterol (2008) 0.91
Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. Liver Int (2009) 0.90
Mechanisms of ocular toxicity using the in vitro bovine lens and sodium dodecyl sulfate as a chemical model. Toxicol Sci (2003) 0.88
Alcohol use while on the liver transplant waiting list: a single-center experience. Liver Transpl (2010) 0.88
Hepatology and the Canadian gastroenterologist: interest, attitudes and patterns of practice: results of a national survey from the Canadian Association of Gastroenterology. Can J Gastroenterol (2003) 0.87
Enhanced activation of memory, but not naïve, B cells in chronic hepatitis C virus-infected patients with cryoglobulinemia and advanced liver fibrosis. PLoS One (2013) 0.86
Differential clustering of bowel biopsy-associated bacterial profiles of specimens collected in Mexico and Canada: what do these profiles represent? J Med Microbiol (2008) 0.86
Third-generation cephalosporin-resistant spontaneous bacterial peritonitis: a single-centre experience and summary of existing studies. Can J Gastroenterol Hepatol (2013) 0.81
MELD score, insulin-like growth factor 1 and cytokines on bone density in end-stage liver disease. World J Hepatol (2011) 0.80
Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience. Transplantation (2016) 0.79
VSL#3 ® probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis. Liver Int (2013) 0.78
Therapies: Drugs, Scopes and Transjugular Intrahepatic Portosystemic Shunt--When and How? Dig Dis (2015) 0.78
Reply to Letter From Thornhill et al.-Infective Endocarditis Hospitalizations Before and After the 2007 American Heart Association Prophylaxis Guidelines. Can J Cardiol (2016) 0.77
Structure-based design of nonpeptide inhibitors of interleukin-1beta converting enzyme (ICE, caspase-1). Bioorg Med Chem (2002) 0.76
Hemodynamics in the immediate post-transplantation period in alcoholic and viral cirrhosis. World J Gastroenterol (2010) 0.76
Soft and hard endpoints in acute variceal bleeding. Hepatology (2015) 0.76
Impact of colon cancer screening on family history phenotype. Epidemiology (2012) 0.75
Cardiac work-up protocol for liver transplant candidates: experience from a single liver transplant centre. Can J Gastroenterol (2012) 0.75
Chronic hepatitis C in Western Canada: a survey of practice patterns among gastroenterologists in Alberta and British Columbia. Can J Gastroenterol Hepatol (2013) 0.75
Portal hypertension and hepatocellular carcinoma: prognosis and beyond. Clin Gastroenterol Hepatol (2006) 0.75
Use of angiotensin-converting enzyme inhibitors after coronary artery bypass grafting in patients with diabetes mellitus. Am J Cardiol (2003) 0.75
Asymptomatic bacteriuria is an independent predictor of urinary tract infections in an ambulatory cirrhotic population: a prospective evaluation. Liver Int (2014) 0.75